Unknown

Dataset Information

0

PD-1/PD-L1 blockade in renal cell cancer.

ABSTRACT: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.

SUBMITTER: Beckermann KE 

PROVIDER: S-EPMC5555220 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

PD-1/PD-L1 blockade in renal cell cancer.

Beckermann Kathryn E KE   Johnson Douglas B DB   Sosman Jeffrey A JA  

Expert review of clinical immunology 20160728 1

<h4>Introduction</h4>Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evid  ...[more]

Similar Datasets

Unknown Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.
| S-EPMC6209395 | biostudies-literature
Unknown Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer.
| S-EPMC7072566 | biostudies-literature
Unknown RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
| S-EPMC5980384 | biostudies-literature
Unknown Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer.
| S-EPMC8222224 | biostudies-literature
Unknown PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
| S-EPMC5290437 | biostudies-literature
Unknown Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade.
| S-EPMC8268315 | biostudies-literature
Unknown Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
| S-EPMC9271774 | biostudies-literature
Unknown Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade.
| S-EPMC8492972 | biostudies-literature
Unknown Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.
| S-EPMC6480014 | biostudies-literature
Unknown PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
| S-EPMC7460585 | biostudies-literature